Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse

NCT01304485 is registered in ClinicalTrials.gov with Phoenix Molecular Imaging as lead sponsor.

NCT NCT01304485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01304485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse
Lead sponsor
Phoenix Molecular Imaging
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
January 31, 2019
Enrollment
2,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer